Pliant Therapeutics, Inc.

PLRX

Healthcare|Biotechnology|US

$0.81

-0.01 (-0.75%)

DCF Value

$0.27

Tangible Book / Share

$2.37

Cash / Share

$2.55

Clinical Trials (8)

Trial	Conditions	Phase	Status	Enrollment	Design	Drug
NCT06270706 A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors	Advanced or Metastatic Solid Tumor	P1	Recruiting	124	Open-label	PLN-101095, PLN-101095, PLN-101095, PLN-101095, PLN-101095, PLN-101095, Pembrolizumab
NCT04072315 Phase 2a Evaluation of PLN-74809 on αvβ6 Receptor Occupancy Using PET Imaging in Participants With IPF/	Idiopathic Pulmonary Fibrosis	P2	Completed	9	Open-label	PLN-74809
NCT04480840 Phase 2a Evaluation of Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Patients With Primary Sclerosing Cholangitis (PSC)	Primary Sclerosing Cholangitis	P2	Completed	121	RCT, Double-blind	PLN-74809, Placebo
NCT04565249 Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Acute Respiratory Distress Syndrome (ARDS) Associated With at Least Severe COVID-19	Acute Respiratory Distress Syndrome, SARS-CoV-2	P2	Terminated	6	RCT, Double-blind	PLN-74809, Placebo
NCT06097260 Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis	Idiopathic Pulmonary Fibrosis	P2	Terminated	320	RCT, Double-blind	PLN-74809, Placebo
NCT05621252 Imaging Evaluation of PLN-74809 in Participants With IPF (PLN-74809)	Idiopathic Pulmonary Fibrosis	P2	Completed	10	RCT, Double-blind	PLN-74809, Placebo
NCT04396756 Evaluation of Efficacy and Safety of PLN-74809 in Patients With Idiopathic Pulmonary Fibrosis	Idiopathic Pulmonary Fibrosis	P2	Completed	120	RCT, Double-blind	PLN-74809, Placebo
NCT03183570 Detection of Integrin avb6 in IPF, PSC, and COVID19 Using PET/CT	Idiopathic Pulmonary Fibrosis, Primary Sclerosing Cholangitis	Early P1	Completed	21	Open-label	[18F]FP-R01-MG-F2